Takeda Pharmaceuticals' Dexilant SoluTab delayed-release orally disintegrating tablets received FDA approval.
Here are four notes:
1. The tablets are a new formulation of dexlansoprazole that can be taken by allowing the tablet to melt in the patient's mouth.
2. Dexilant SoluTab is a proton pump inhibitor indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease, the maintenance of healed erosive esophagitis and relief of heartburn in adults.
3. It also includes dual delayed release technology to provide two separate releases of medication.
4. In addition to Dexilant SoluTab, Dexilant is also available as a capsule, which has been available for nearly seven years.